文献速递外周动脉疾病

美国医保受益人CLTI腔内血运重建的地域差异(2016-2023)

Geographic variation in endovascular revascularization for chronic limb-threatening ischemia care among Medicare beneficiaries (2016-2023).
PubMed 文献 · J Vasc Surg · 2025-07-28

基于2016-2023年381,173例Medicare按服务收费受益人因慢性肢体威胁性缺血(CLTI)接受腔内血运重建的数据,评估美国东北、南、中西部和西部四个区域的血运重建分布、医疗利用和结局差异。中西部主要结局(死亡或大截肢复合)风险最高(HR 1.20),南部和西部也高于东北部;中西部术前术后血管专科门诊就诊率最低。

要点

  • 南部承担了研究期间52.18%的CLTI腔内血运重建,中西部仅13.9%。
  • 调整后中西部主要结局风险最高(HR 1.20;95%CI 1.18,1.22;P<.0001),高于东北部。
  • 中西部术前和术后血管专科门诊就诊率均最低(调整率比0.73;95%CI 0.72,0.74)。

核心结论

  • 美国各区域CLTI腔内血运重建的医疗可及性和结局存在差异,中西部风险最高。

研究设计与样本

  • 回顾性队列研究,纳入2016-2023年Medicare按服务收费受益人所有CLTI腔内血运重建,共381,173例,按美国四区域分层,中位随访625天。

主要发现

  • 南部实施52.18%的血运重建,西部17.3%,东北部16.2%,中西部13.9%。
  • 调整后主要结局风险中西部最高(HR 1.20;95%CI 1.18,1.22;P<.0001),南部HR 1.11(95%CI 1.10,1.13;P<.0001),西部HR 1.04(95%CI 1.02,1.06;P<.0001),均以东北部为参照。
  • 中西部术前血管专科门诊调整率比0.73(95%CI 0.72,0.74;P<.0001),术后同样为0.73(95%CI 0.72,0.74;P<.0001),均为各区域最低。

临床怎么用

  • 应关注中西部农村和经济弱势区域CLTI患者的血运重建后随访和血管专科接触。
  • 针对区域差异优化医疗可及性,可能改善CLTI患者的截肢和死亡结局。

局限性

  • 仅纳入Medicare按服务收费受益人,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Chronic limb-threatening ischemia (CLTI), the most severe manifestation of peripheral artery disease, is associated with high risk of major amputation and mortality. Although timely revascularization is a cornerstone of CLTI management, disparities in access to care and outcomes persist across U.S. geographic regions. This study aims to evaluate variations in endovascular revascularization for CLTI, health care utilization patterns, and outcomes stratified by U.S. regions to inform how we address these disparities. METHODS: From 2016 through 2023, all endovascular revascularizations for CLTI among Medicare fee-for-service beneficiaries were included and evaluated by Northeast, South, Midwest, and West regions of the United States. Follow-up continued through December 31, 2023, with a median duration of 625 days (maximum 2921 days). The primary outcome was a composite of death or major amputation. Secondary outcomes included major amputation, all-cause mortality, repeat revascularization, change in ambulatory status, and health care utilization before and after revascularization. Multivariable Cox proportional hazards regression models were used to adjust for demographic, clinical, and procedural characteristics. RESULTS: Among 381,173 beneficiaries, the South performed more than half of all revascularizations throughout the study period (52.18%), followed by the West (17.3%), Northeast (16.2%), and the Midwest (13.9%). After adjustment, the Midwest showed the highest risk for the primary outcome (hazard ratio [HR]: 1.20; 95% confidence interval [CI]: 1.18, 1.22; P < .0001), followed by the South (HR: 1.11; 95% CI: 1.10, 1.13; P < .0001) and West (HR: 1.04; 95% CI: 1.02, 1.06; P < .0001), all compared with the Northeast. Health care utilization analyses revealed fewer outpatient visits with a vascular provider before and after revascularization in all regions compared with the Northeast with the lowest rates in the Midwest (before revascularization: adjusted rate ratio: 0.73; 95% CI: 0.72, 0.74; P < .0001; after revascularization: adjusted rate ratio: 0.73; 95% CI: 0.72, 0.74; P < .0001). CONCLUSIONS: Disparities in access to care and outcomes persist across U.S. regions for Medicare beneficiaries with CLTI and influence health care utilization and outcomes. The Midwest region, in particular, that cares for a high proportion of rural patients experiences the greatest risks of amputation and death related to CLTI, which may in part be due to less frequent health care contact after revascularization. Targeted improvements in health care access, especially in rural and economically disadvantaged regions, are needed to enhance outcomes in patients with CLTI.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Kim JM, Li S, Song Y, et al. Geographic variation in endovascular revascularization for chronic limb-threatening ischemia care among Medicare beneficiaries (2016-2023). J Vasc Surg. 2025. PMID: 40738231. doi:10.1016/j.jvs.2025.07.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。